Orchard, a UK/US hybrid gene therapy company, is taking the ax to therapies for rare primary immune deficiencies. These include: OTL-103 for ...
https://www.google.com/url?rct=j&sa=t&url=https://endpts.com/as-shares-tank-orchard-once-again-restructures-shedding-gene-therapy-programs-and-a-large-part-of-the-staff/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw1GaTaPrfyP1lw0kiM8zLZQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.